Outcome Measures: |
Primary: To assess the safety of a single topical dose of PRT-201. To assess the effect on the diameter of and blood flow through the AVF outflow vein., 2 & 6 weeks after AVF creation | Secondary: The proportion of patients with AVF patency, AVF maturation, and AVF use for hemodialysis., 3, 6, 9, and 12 months
|
Locations: |
Clarian Health Partners/Indiana University/Purdue University, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|Maine Medical Center, Portland, Maine, 04102, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Western New England Renal & Transplant Associates, Springfield, Massachusetts, 01104, United States|Washington University in St. Louis, St. Louis, Missouri, 63110, United States|Weill Cornell Medical College, New York, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45267, United States|The Methodist Hospital, Houston, Texas, 77030, United States|Sentara Medical Group, Norfolk, Virginia, 23507, United States
|